Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Literature
1.
Kubo M, Kawai M, Kumamaru H et al (2019) A population-based recurrence risk management study of patients with pT1 node-negative HER2+ breast cancer: a National Clinical Database study. Breast Cancer Res Treat 178(3):647–656CrossRef
2.
Edge SB, Byrd DR, Compton CC et al (2009) AJCC cancer staging manual, 7th edn. Springer, New York
3.
Karakas Y, Dizdar O, Aksoy S (2018) The effect of total size of lesions in multifocal/multicentric breast cancer on survival. Clin Breast Cancer 18(4):320–327CrossRef
Metadata
Title
Do multifocal or multicentric pT1a node-negative HER2+ breast cancers get benefit from systemic treatment?
Author
Kadri Altundag
Publication date
01-02-2020
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2020
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-019-05508-1

Other articles of this Issue 3/2020

Breast Cancer Research and Treatment 3/2020 Go to the issue

Epidemiology

Weight trajectories in women receiving systemic adjuvant therapy for breast cancer

Clinical trial

Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?

Preclinical Study

The orphan nuclear receptor estrogen-related receptor beta (ERRβ) in triple-negative breast cancer

Preclinical study

Clinicopathological significance of lipocalin 2 nuclear expression in invasive breast cancer

Epidemiology

Socioeconomic status differs between breast cancer patients treated with mastectomy and breast conservation, and affects patient-reported preoperative information

Preclinical study

Evaluation of the anti-Thomsen–Friedenreich antibodies Nemod-TF1 and Nemod-TF2 as prognostic markers in breast cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits